Abeona Therapeutics (ABEO) Trading Down 9.5%

Abeona Therapeutics Inc (NASDAQ:ABEO)’s share price fell 9.5% during mid-day trading on Friday . The company traded as low as $7.48 and last traded at $7.52. 543,459 shares were traded during trading, an increase of 35% from the average session volume of 403,457 shares. The stock had previously closed at $8.31.

A number of research firms have recently issued reports on ABEO. BidaskClub upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, February 21st. ValuEngine downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Thursday, December 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $26.00.

The stock has a market cap of $360.58 million, a P/E ratio of -6.32 and a beta of 1.93.



Large investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Abeona Therapeutics by 1.6% during the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after acquiring an additional 35,610 shares during the last quarter. Sphera Funds Management LTD. lifted its position in Abeona Therapeutics by 51.0% during the third quarter. Sphera Funds Management LTD. now owns 336,939 shares of the biopharmaceutical company’s stock valued at $4,313,000 after acquiring an additional 113,767 shares during the last quarter. Teachers Advisors LLC lifted its position in Abeona Therapeutics by 75.6% during the third quarter. Teachers Advisors LLC now owns 98,192 shares of the biopharmaceutical company’s stock valued at $1,257,000 after acquiring an additional 42,261 shares during the last quarter. Trexquant Investment LP purchased a new stake in Abeona Therapeutics during the third quarter valued at approximately $163,000. Finally, Allianz Asset Management GmbH lifted its position in Abeona Therapeutics by 9.4% during the third quarter. Allianz Asset Management GmbH now owns 110,649 shares of the biopharmaceutical company’s stock valued at $1,416,000 after acquiring an additional 9,465 shares during the last quarter. 67.93% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/03/24/abeona-therapeutics-abeo-trading-down-9-5.html.

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: Systematic Risk

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.